Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹24 Cr
Revenue (TTM)
₹16 Cr
Net Profit (TTM)
₹1 Cr
ROE
8.4 %
ROCE
10 %
P/E Ratio
26.9
P/B Ratio
2.1
Industry P/E
26.59
EV/EBITDA
15.3
Div. Yield
0 %
Debt to Equity
0.4
Book Value
₹38.1
EPS
₹3
Face value
10
Shares outstanding
2,990,300
CFO
₹1.32 Cr
EBITDA
₹6.95 Cr
Net Profit
₹5.29 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ishita Drugs
| -0.3 | 12.4 | -0.9 | -3.6 | 17.3 | 21.4 | 18.9 |
|
BSE Healthcare
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ishita Drugs
| -16.0 | 21.1 | 39.0 | 11.9 | 47.1 | 163.5 | -25.7 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ishita Drugs
|
79.8 | 23.9 | 16.2 | 0.9 | 5.3 | 8.1 | 26.9 | 2.1 |
| 2,791.2 | 34,920.1 | 5,201.6 | 1,014.6 | 22.9 | 25 | 34.4 | 7.6 | |
| 7,827.5 | 19,544.3 | 2,177.5 | 200.9 | 11.3 | 26.5 | 97.3 | 23.5 | |
| 1,565.8 | 11,917.5 | 2,089.5 | 622.0 | 31.3 | 20.4 | 19.4 | 3.6 | |
| 1,332.1 | 18,429.0 | 3,078.2 | 469.4 | 26.4 | 14.9 | 42.7 | 5.1 | |
| 1,961.1 | 31,410.1 | 4,193.0 | 753.8 | 22.7 | 20.8 | 41.7 | 7.8 | |
| 4,887.1 | 22,333.8 | 2,482.3 | 853.6 | 33.7 | 18.9 | 26.2 | 5.6 | |
| 4,778.6 | 7,918.9 | 1,348.5 | 293.5 | 28.1 | 50.7 | 27 | 11.4 | |
| 388.9 | 7,603.2 | 1,432.0 | 149.0 | 19.1 | 7.9 | 50.7 | 3.1 | |
| 971.2 | 8,938.5 | 4,725.6 | 528.7 | 14.9 | 20.7 | 17.5 | 3.0 |
No Review & Analysis are available.
Ishita Drugs & Industries Limited manufactures and sells active pharma ingredients and drug intermediates in India. It offers active pharma ingredients, such as sulfa drugs/sulfonamides, vitamins, fluoro quinolones, antibiotics, anthelmintics,... iodides and citrates, food additives/excipients, and others; fine chemicals; and drug intermediaries, as well as finished dosage forms. The company also provides contract manufacturing services for various drug intermediates, fine chemicals, or specialty chemicals. It serves regulatory authorities and pharmaceutical companies. The company exports its products to approximately 25 countries. Ishita Drugs & Industries Limited was incorporated in 1992 and is based in Ahmedabad, India. Read more
Incorporated
1992
Chairman
--
Managing Director
Jagdish Agrawal
Headquarters
Ahmedabad Dist, Gujarat
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Ishita Drugs & Industries Ltd is ₹79.75 (BSE) as of 02-Apr-2026 IST. Ishita Drugs & Industries Ltd has given a return of 17.29% in the last 3 years.
The P/E ratio of Ishita Drugs & Industries Ltd is 26.86 times as on 02-Apr-2026, a 1 premium to its peers’ median range of 26.59 times.
The P/B ratio of Ishita Drugs & Industries Ltd is 2.09 times as on 02-Apr-2026, a 53 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
27.05
|
2.18
|
|
2024
|
26.20
|
1.98
|
|
2023
|
25.59
|
1.61
|
|
2022
|
15.36
|
1.44
|
|
2021
|
10.81
|
1.15
|
The 52-week high and low of Ishita Drugs & Industries Ltd are Rs 90.85 and Rs 66.00 as of 05-Apr-2026.
Ishita Drugs & Industries Ltd has a market capitalisation of ₹ 24 Cr as on 02-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Ishita Drugs & Industries Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹9.10
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.